Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581101 | 0.77 | KDM4C (0.49) | KDM4EKMT2AKDM4C | |
| SCHEMBL4579443 | 0.75 | CCNC (0.45) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4581250 | 0.74 | HDAC3 (0.47) | MMP2KDM4EKMT2AMAPTRAB9A | |
| SCHEMBL4582783 | 0.74 | KDM4E (0.49) | KDM4EKMT2AMAPTKDM4C | |
| SCHEMBL4581093 | 0.74 | KDM4E (0.58) | MMP2KDM4EKMT2AMAPTTDP1 | |
| SCHEMBL4580845 | 0.73 | MMP2 (0.46) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4580442 | 0.73 | P4HTM (0.43) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4579902 | 0.72 | CCNC (0.43) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4579533 | 0.72 | ADRA2A (0.47) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4581648 | 0.72 | AURKA (0.47) | KDM4EKMT2AMAPTKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | MMP2 900/4885CCNC 289/4885CDK8 516/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | MMP2 900/4885CCNC 289/4885CDK8 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.